CO2022018389A2 - Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2), y usos de los mismos para propósitos de vacuna - Google Patents

Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2), y usos de los mismos para propósitos de vacuna

Info

Publication number
CO2022018389A2
CO2022018389A2 CONC2022/0018389A CO2022018389A CO2022018389A2 CO 2022018389 A2 CO2022018389 A2 CO 2022018389A2 CO 2022018389 A CO2022018389 A CO 2022018389A CO 2022018389 A2 CO2022018389 A2 CO 2022018389A2
Authority
CO
Colombia
Prior art keywords
cov
sars
polypeptides
inventors
vaccine purposes
Prior art date
Application number
CONC2022/0018389A
Other languages
English (en)
Spanish (es)
Inventor
Yves Levy
Gérard Zurawski
Sandra Zurawski
Christine Lacabaratz
Sylvain Cardinaud
Mathieu Surenaud
Original Assignee
Inst Nat Sante Rech Med
Baylor Res Institute
Assist Publique Hopitaux Paris Aphp
Univ Paris Val De Marne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Baylor Res Institute, Assist Publique Hopitaux Paris Aphp, Univ Paris Val De Marne filed Critical Inst Nat Sante Rech Med
Publication of CO2022018389A2 publication Critical patent/CO2022018389A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pulmonology (AREA)
CONC2022/0018389A 2020-05-26 2022-12-19 Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2), y usos de los mismos para propósitos de vacuna CO2022018389A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20305550 2020-05-26
EP20306415 2020-11-20
EP21305092 2021-01-26
EP21305482 2021-04-12
PCT/EP2021/064098 WO2021239838A2 (en) 2020-05-26 2021-05-26 Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes

Publications (1)

Publication Number Publication Date
CO2022018389A2 true CO2022018389A2 (es) 2023-02-06

Family

ID=76159441

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0018389A CO2022018389A2 (es) 2020-05-26 2022-12-19 Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2), y usos de los mismos para propósitos de vacuna

Country Status (9)

Country Link
US (1) US20230212231A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157343A2 (cg-RX-API-DMAC7.html)
JP (2) JP7858550B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230042222A (cg-RX-API-DMAC7.html)
BR (1) BR112022024063A2 (cg-RX-API-DMAC7.html)
CA (1) CA3184802A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022018389A2 (cg-RX-API-DMAC7.html)
MX (1) MX2022014943A (cg-RX-API-DMAC7.html)
WO (1) WO2021239838A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108373509A (zh) * 2009-03-10 2018-08-07 贝勒研究院 靶向抗原呈递细胞的抗病毒疫苗
WO2022043551A2 (en) * 2020-08-31 2022-03-03 Curevac Ag Multivalent nucleic acid based coronavirus vaccines
JP2024540505A (ja) * 2021-11-17 2024-10-31 アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル ユニバーサルサルベコウイルスワクチン
CN114807179B (zh) * 2022-06-01 2022-10-21 广州达博生物制品有限公司 一种新型冠状病毒肺炎疫苗的构建与应用
WO2025023616A1 (ko) * 2023-07-21 2025-01-30 세종대학교산학협력단 항 cd98 단일클론항체 및 이의 용도

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
CN100588430C (zh) * 2004-02-20 2010-02-10 复旦大学 基于表位的SARS-Cov基因疫苗及其构建
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP2684889A3 (en) 2007-02-02 2014-03-05 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010009346A2 (en) 2008-07-16 2010-01-21 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
BRPI1009454A2 (pt) * 2009-03-10 2019-09-24 Baylor Res Institute vacinas contra o câncer direcionadas a células apresentadoras de antígenos
US8345509B2 (en) 2009-04-16 2013-01-01 Chevron U.S.A., Inc. System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole
WO2011032161A2 (en) 2009-09-14 2011-03-17 Baylor Research Institute Vaccines directed to langerhans cells
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
KR20130108295A (ko) 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
WO2014085580A1 (en) * 2012-11-28 2014-06-05 Baylor Research Institute Methods and compositions involving a flu vaccine
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
TR201811077T4 (tr) 2013-09-06 2018-08-27 Aurigene Discovery Tech Ltd İmmünomodülatörler olarak 1,3,4-oksadiazol ve 1,3,4-tiyadiyazol türevleri.
US10849972B2 (en) * 2018-11-27 2020-12-01 King Adulaziz University Trimeric S1-CD40L fusion protein vaccine against Middle East respiratory syndrome-coronavirus
IT202000009625A1 (it) * 2020-04-30 2021-10-30 Takis S R L Polinucleotidi codificanti antigeni di sars-cov-2 e relativo uso in campo medico come vaccini.

Also Published As

Publication number Publication date
BR112022024063A2 (pt) 2023-01-31
MX2022014943A (es) 2023-03-08
JP2023528017A (ja) 2023-07-03
WO2021239838A3 (en) 2022-03-17
KR20230042222A (ko) 2023-03-28
EP4157343A2 (en) 2023-04-05
JP2026062799A (ja) 2026-04-10
US20230212231A1 (en) 2023-07-06
WO2021239838A2 (en) 2021-12-02
CA3184802A1 (en) 2021-12-02
JP7858550B2 (ja) 2026-05-14

Similar Documents

Publication Publication Date Title
AR122050A2 (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
BR112022024063A2 (pt) Polipeptídeos de coronavírus 2 da síndrome respiratória aguda grave (sars-cov-2) e usos dos mesmos para fins de vacina
CL2023000264A1 (es) Nuevos vectores virales adeno-asociados dirigidos al hígado
MX2019011599A (es) Moleculas quimericas y usos de las mismas.
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
MX2019010275A (es) Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este.
CL2024001715A1 (es) Anticuerpo aislado que se une a la proteína e del virus del dengue; y uso.
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
EA033386B1 (ru) Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение
EA201891415A1 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
AR102006A1 (es) Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos
AR109528A1 (es) Mutaciones estabilizantes de trímeros de proteínas de la envoltura del vih
AR134554A2 (es) Composición inmunológica o de vacuna y método para producir una respuesta protectora contra prrsv en un animal
AR110632A1 (es) Vectores del adenovirus canino
MX345150B (es) Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1.
MX391149B (es) Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.
MX387400B (es) Células de mamífero que expresan antígenos de citomegalovirus.
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
CO2017001614A2 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
MX2019007924A (es) Vacunas contra la influenza.
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
MX2018008797A (es) Vacunas contra el cancer.